Ali Cansu1, Ayse Serdaroglu, Peyami Cinaz. 1. Department of Pediatric Neurology, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey. acansu2003@yahoo.com
Abstract
PURPOSE: The aim of this study was to investigate whether oxcarbazepine (OXC) monotherapy causes weight gain in epileptic children. METHODS: A total of 22 children with epilepsy (age 3.0-16.4 years) were assigned to OXC therapy. Serum levels of glucose, insulin, cortisol, leptin, neuropeptide Y (NPY), galanin and ghrelin were assessed before OXC therapy (month 0) and after the 6th and 18th months. RESULTS: There was no statistically significant difference in weight-standard deviation score (SDS), Height-SDS, BMI-SDS, serum glucose, insulin, cortisol, leptin, NPY, galanin and ghrelin levels between initial values (month 0) and those in the 6th and 18th months after OXC therapy (p > 0.05). CONCLUSIONS: Our results indicate that OXC therapy causes neither weight change nor alterations in serum glucose, insulin, cortisol, leptin, NPY, galanin and ghrelin levels in children with epilepsy.
PURPOSE: The aim of this study was to investigate whether oxcarbazepine (OXC) monotherapy causes weight gain in epilepticchildren. METHODS: A total of 22 children with epilepsy (age 3.0-16.4 years) were assigned to OXC therapy. Serum levels of glucose, insulin, cortisol, leptin, neuropeptide Y (NPY), galanin and ghrelin were assessed before OXC therapy (month 0) and after the 6th and 18th months. RESULTS: There was no statistically significant difference in weight-standard deviation score (SDS), Height-SDS, BMI-SDS, serum glucose, insulin, cortisol, leptin, NPY, galanin and ghrelin levels between initial values (month 0) and those in the 6th and 18th months after OXC therapy (p > 0.05). CONCLUSIONS: Our results indicate that OXC therapy causes neither weight change nor alterations in serum glucose, insulin, cortisol, leptin, NPY, galanin and ghrelin levels in children with epilepsy.
Authors: Victor Mazereel; Johan Detraux; Davy Vancampfort; Ruud van Winkel; Marc De Hert Journal: Front Endocrinol (Lausanne) Date: 2020-10-09 Impact factor: 5.555